The novel tumor suppressor IRF2BP2 regulates Hippo pathway
Source:
Time: 2020-03-17
HCC is one of the few tumors with high morbidity, high mortality and poor prognosis worldwide.
The Hippopathway, evolutionarily conserved from
Drosophila to mammals, precisely controls organ size and tumorigenesis by restricting the oncogenic activity of YAP. However, therapies targeting YAP for the prevention and treatment of HCC remain limited.
This study reveals the clinical relevance and the feedback regulatory loop between the tumor suppressor IRF2BP2 and the oncogene
YAPin HCC. The data show that IRF2BP2 is a novel target gene repressed by the YAP-TEAD transcriptional complex, and
exhibits potent antitumor activityby inhibiting YAP activity. The
researchersidentify that IRF2BP2 interacts with VGLL4 and stabilizes the protein level of VGLL4, which leads to synergistic inhibition toward YAP. Furthermore, liver-specific IRF2BP2 overexpression strongly suppresses liver tumor formation induced by Hippo pathway inactivation. These findings identify a novel
IRF2BP2-VGLL4-
YAPfeedback loop revealing the role and the molecular mechanism of how IRF2BP2 associates with Hippo pathway to regulate liver cancer progression, which may propose a potential strategy for HCC therapy and diagnosis.
FENG Xue, LU Tiantian and their colleagues who are from the research group led by
Prof. ZHANG Lei, TIAN Wei and CHENG Shuqun completed this work. The work was financially supported by the National Natural Science Foundation of China, National Key Research and Development Program of China, “Strategic Priority Research Program” of Chinese Academy of Sciences, Shanghai Program, Science and Technology Commission of Shanghai Municipality, Youth Innovation Promotion Association of the Chinese Academy of Sciences and China Postdoctoral Science Foundation.
The model of IRF2BP2 and Hippo pathway-mediated feedback loop in regulating the development of hepatocellular carcinoma
Reference: https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.30961